PODESTA GROUP, INC. for GENZYME
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare issues related to end stage renal disease. Monitor debt ceiling negotiations. ASP changes. 340B issues. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365 / Pub. L. 112-25, Budget Control Act of 2011. Medicare reimbursement issues.
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Line 27, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRISTINA ANTELO | — |
| SHARON COHEN | — |
| ANTHONY PODESTA | — |
Budget/Appropriations BUD
FY 2012 budget appropriations. Monitor debt ceiling negotiations. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365 / Pub. L. 112-25, Budget Control Act of 2011. H.R. 2112, Agriculture Appropriations.
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Line 27, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Pharmacy PHA
Prescription Drug User Fee Act reauthorization. H.R. 2112, Agriculture Appropriations. H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365 / Pub. L. 112-25, Budget Control Act of 2011. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). Product exclusivity issues.
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Line 27, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Health Issues HCR
340B issues Monitor debt ceiling negotiations. Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). H.R. 2017, Continuing Appropriations Act, 2012. H.R. 2608, Continuing Appropriations Act, 2012. S. 365 / Pub. L. 112-25, Budget Control Act of 2011.
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Line 27, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CRISTINA ANTELO | — |
| SHARON COHEN | — |
| ANTHONY PODESTA | — |
Copyright/Patent/Trademark CPT
H.R. 1249 / S. 23, America Invents Act.
Foreign entity interest: As the ultimate parent of Genzyme Corporation, Sanofi-aventis, identified on Line 27, has an interest in the issues lobbied.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.